logo-loader
HealthPharma & Biotech
Genus plc

Genus gets first results in US cattle sexing case

The technology is important because there's a big market for dairy farmers, which want female calves (to produce milk).

08.jpg
Mooving on - the first decisions are out from the court in Wisconsin

Genus plc (LON: GNS) is awaiting US court rulings concerning its GSS technology for sexing cattle semen.

The technology is important because there's a big market for dairy farmers, which want female calves (to produce milk).

A commercial launch of GSS product would increase competition in the market for the processing of sexed bovine semen and that's what's really at the heart of the court case in Wisconsin.

At the trial yesterday, the jury found that Genus and its firm ABS had proved that Inguran LLC, operating then as Sexing Technologies (ST), had maintained monopoly power in the market for sexed bovine semen processing in the US since July 2012.

But the jury also found that Genus had not proved that it had suffered injury as a result.

But the case is not over. The jury still has to consider ST's counter claims related to two of its US patents and ST's counter claims that Genus breached confidentiality obligations under the 2012 semen sorting agreement between the parties and it will also consider, if applicable, a verdict on damages in relation to these matters later this week.

Quick facts: Genus plc

Price: £28.50

Market: LSE
Market Cap: £18.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan 'driving research for novel drug development for rare diseases'

Proactive London sits down with Open Orphan PLC's (LON:ORPH) chief operating officer Maurice Treacy. Treacy discusses how he became involved with Open Orphan and his ambitions for the firm's health data initiative. ''Many rare diseases aren't known or badly diagnosed ... but rare isn't...

2 hours, 9 minutes ago

2 min read